Gubra A S (GUBRF) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. My name is Gail, and I will be your operator for today. At this time, I would like to welcome each and every one of you to the group first quarter 2025 earnings release. All lines have been placed on mute to prevent any background noise. After the speech remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, kindly press star one again. Thank you. It is now my pleasure to turn today's call over to Gubre to start the presentation. Please go ahead. Thank you very much, Operator. It's our pleasure today to present first quarter results for you. Starting out, GUPRA is a hybrid business model company. We are experts in preclinical research into metabolic disease and neighboring scientific areas. We have built a core research accelerator, meaning we have all the labs and testing facilities in-house in order to progress preclinical programs. And this core research accelerator we use to provide services to external clients as well as to mature our internal research programs so that is the cro business the external clients and the pipeline business the dnp business for the internal programs Today we are roughly 270 colleagues and in the service part of Goobra, we're working with a long list of various clients, 16 out of top 20 pharma companies in the world either are or have been clients of Goobra. So diving into the update from the recent quarter, The biggest piece of news was, of course, our landmark agreement with AbbVie on the Group AMI Ameline program. According to the terms of the agreement, we are granting AbbVie a global right to develop and commercialize Group AMI for variou...